21 May 2013 07:00

For immediate release | 21 May 2013 |
Â
Â
Â
Futura Medical PLC
("Futura" or the "Company")
Â
Notification of Interim Results
Â
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, will announce its interim results for the six months ended 30 June 2013 on Thursday 12 September 2013.
Â
A briefing for analysts will be held at 10.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London, EC2V 6DN.
Â
For more information, or to register attendance, please contact Buchanan on 020 7466 5000.
Â
Â
For any further information please contact:
Â
Futura Medical plc | |
James Barder, Chief Executive  | Tel: +44 (0)1483 685 670 |
mail to: james.barder@futuramedical.com | www.futuramedical.com |
Nomura Code Securities Limited | |
Phil Walker / Giles Balleny | Tel:+44 (0)20 7776 1200 |
For media enquiries please contact: | |
Buchanan | |
Mark Court / Fiona Henson / Sophie Cowles www.buchanan.uk.com  | Tel: +44 (0)20 7466 5000 |
Â
Â
Notes to Editors
Â
Futura Medical plc
Â
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Â
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com